EverSource Wealth Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

EverSource Wealth Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$373	Sell	11 -1	-8%	-$33	﹤0.01%	4174
2026 Q1	$384	Buy	12 +4	+50%	+$130	﹤0.01%	4106
2025 Q4	$281	Hold	8	–	–	﹤0.01%	3977
2025 Q3	$228	Hold	8	–	–	﹤0.01%	4084
2025 Q2	$145	Buy	8 +6	+300%	+$109	﹤0.01%	4085
2025 Q1	$41	Buy	+2	New	+$44	﹤0.01%	3912

Other funds holding NAMS

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

MMC

Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EverSource Wealth Advisors's NAMS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 8.3% in Q2 2026, selling an estimated $33 and leaving 11 shares worth $373. The position accounts for ﹤0.01% of the portfolio, ranked #4174.

EverSource Wealth Advisors first reported a position in NAMS in Q1 2025 and has held it in 6 quarters since. The position peaked at $384 in Q1 2026. 40 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

EverSource Wealth Advisors held 11 shares of NewAmsterdam Pharma worth $373 as of Q2 2026.
EverSource Wealth Advisors sold 1 NewAmsterdam Pharma share in Q2 2026, an estimated $33.
NewAmsterdam Pharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4174 holding.
EverSource Wealth Advisors first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 6 quarters since.
EverSource Wealth Advisors's NewAmsterdam Pharma position peaked at $384 in Q1 2026.
40 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.